Chiefy is a hospital and health care company that specializes in zero waste and zero harm in surgery. Chiefy makes it easy for surgeons, anesthesiologists, nurses, and other stakeholders to align on the case plan earlier through asynchronous virtual huddles. It captures lessons, notes, and feedback after procedures and drives continuous improvement. With Chiefy, quality and communication best practices are seamlessly baked into daily operations, helping teams collaborate strikingly smarter and get closer to patients. Founded by Maya Ber Lerner and Assaf Ziv in 2020, it is located in New York, New York.
Formulator is a mental healthcare platform designed to enhance the productivity and accessibility of mental health services for patients and healthcare providers. It provides a structured case formulation tool that assists individuals in articulating their situations and goals, which can then be shared with their clinicians. This approach allows for a more focused dialogue between patients and therapists, enabling healthcare professionals to address core issues effectively from the outset. By facilitating better communication and understanding, Formulator aims to optimize the care experience for both patients and providers.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, focused on developing a metabolism-based liquid biopsy platform for the early detection and monitoring of cancer. Founded in 2017, Elypta's platform utilizes a new in vitro diagnostic laboratory assay kit to measure biomarkers in blood and urine, employing artificial intelligence algorithms to analyze data for cancer signatures. The company is actively involved in the clinical trial series AURORAX, which investigates the application of its technology in renal cell carcinoma, addressing aspects such as recurrence surveillance and treatment response monitoring. Elypta is exploring its platform's potential across various cancer indications, aiming to enhance early-stage cancer detection and improve patient outcomes.
MedaSystems operates a cloud-based platform that facilitates collaboration between life science companies and healthcare providers regarding access to experimental therapies. The platform streamlines the management of requests for investigational medicines by incorporating configurable workflows and a form builder that captures complex, structured data specific to therapies. It also features task management and tracking capabilities, as well as integration with machine learning libraries. This comprehensive approach enables manufacturers to effectively work with physicians on various request types, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access.
Quantivly, Inc. is a company that specializes in artificial intelligence solutions tailored for the field of radiology. Established in 2019 and located in Somerville, Massachusetts, Quantivly has developed a software platform focused on MRI and radiology information management. This platform is designed to manage and analyze MRI imaging workflows by processing, cleaning, and harmonizing scanner data. By creating a queryable, vendor-neutral repository of operational knowledge, Quantivly empowers radiology departments and imaging centers to make informed, data-driven decisions. In doing so, it aims to facilitate new research opportunities and improve the overall patient experience.
Neucruit is a government-backed venture that utilizes deep tech to build digital patient recruitment strategies to improve the lives of patients and clinical innovators. The London, England-based company was founded in 2019.
Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.
hi.health offers people with private health insurance convenient and safe access to health care billing via app or web. Users can easily submit their invoices digitally and hi.health takes care of the further processing, billing and customer service providing a seamless user experience. With the integrated “library” users receive a transparent overview of relevant digital health products and services, that are (partially) covered by their insurance. hi.health operates at the intersection of digital health, fintech and insurtech. While each of these rapidly growing markets are already exciting in themselves, their combination in one product is unique. The company was founded by Sebastian Gruber and Fredrik Debong in July 2019. Since hi.health launched in Germany at the end of 2019 several thousand users already use the independent billing app.
We are a technology company which provides a platform called “Medall”. Medall is a web application to enable healthcare professionals and students to connect in a professional network, to store, organise and display their professional achievements and to facilitate collaboration between, and professional matching of, users of the application based on their development needs and existing skills. Medall also enables healthcare organisations (“Organisational Users”) to promote their organisational aims, to communicate with members, to offer training, content, poster halls, certificates and events to members and to participate in discussions and development involving matters of healthcare.
We are a technology company which provides a platform called “Medall”. Medall is a web application to enable healthcare professionals and students to connect in a professional network, to store, organise and display their professional achievements and to facilitate collaboration between, and professional matching of, users of the application based on their development needs and existing skills. Medall also enables healthcare organisations (“Organisational Users”) to promote their organisational aims, to communicate with members, to offer training, content, poster halls, certificates and events to members and to participate in discussions and development involving matters of healthcare.
Cardiomatics uses artificial intelligence tools for Cardiology. Their service uses global HIPAA compliant services that guarantee safety, and accessibility from anywhere in the world. The effectiveness of their algorithms has been verified on the benchmark database developed by Boston's Beth Israel Hospital and MIT. Cardiomatics was founded in 2017 and is based in Poland.
Lena develops a social event information application software designed for senior citizens. The company specializes in developing an app that introduces seniors to events they love in their own communities. It enables users to connect to social circles, and encourage them to participate in activities through gamified rewards.
Cardiomatics uses artificial intelligence tools for Cardiology. Their service uses global HIPAA compliant services that guarantee safety, and accessibility from anywhere in the world. The effectiveness of their algorithms has been verified on the benchmark database developed by Boston's Beth Israel Hospital and MIT. Cardiomatics was founded in 2017 and is based in Poland.
Developer of a digital healthcare technology designed to collect and analyze data on the outcomes of care. The company's technology helps to anticipate how one will feel before starting any treatment, track progress during treatment, and offers information about the clinical conditions, symptoms, treatment, recovery, and healthy living strategies validated by doctors, enabling patients to have a follow-up of the outcomes of their medical treatments.
EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.
moveUP develops and commercialise digital therapeutics solutions. Its closed loop system enables high compliance, better outcome and satisfaction. It uses continuously collected data to directly personalise the treatment of the patient. Its first therapy treats orthopaedic patients undergoing a joint surgery. It has CE medical device & ISO 13485 certification.
contextflow GmbH develops and provides machine learning and artificial intelligence (AI) based solutions for radiology image search and analysis. It offers 3D image-based information search solution, which delivers summary of clinical findings, similar reference cases, and associated differential diagnosis for supporting decisions. The company has strategic partnerships with Radiology Center, Boehringer Ingelheim, and Austrian Lung Fibrosis Association. contextflow GmbH was founded in 2016 and is headquartered in Vienna, Austria.
Replica Analytics Ltd. is a company based in Ottawa, Canada, that specializes in developing modeling software for creating synthetic data derived from real clinical datasets. Established in 2019, the company focuses on generating privacy-protective synthetic data that retains the statistical characteristics of actual data. Its software technologies also include privacy assurance features to ensure the security and confidentiality of the generated datasets. By leveraging these innovative solutions, Replica Analytics addresses the growing need for data privacy in clinical research and analytics.
BioLib Technologies ApS is a Copenhagen-based company founded in 2019 that specializes in bioinformatic data analytics. The company operates a platform designed to facilitate the analysis of biological data, providing access to various datasets, analytic workflows, algorithms, and cloud-computing infrastructure. BioLib's comprehensive services aim to streamline the process of transforming raw experimental data into actionable insights for new treatments and diagnostics. By offering scientific support and fostering a collaborative environment, BioLib enables organizations to accelerate their scientific discoveries in genomics and healthcare.
Segmed, Inc. is a cloud-based platform that specializes in providing curated and anonymized radiology data for medical companies, primarily focused on supporting the development of artificial intelligence in healthcare. Founded in 2019 and headquartered in Menlo Park, California, Segmed's platform offers customized datasets tailored to the specific needs of its clients. The company aims to ensure that the data utilized for developing medical AI is diverse and representative, thereby reducing biases in healthcare applications. By building a robust infrastructure for accessing de-identified, structured medical imaging data, Segmed facilitates the creation of early disease detection and prediction models, ultimately contributing to the improvement of global healthcare outcomes.
PlenOptika, Inc. is a Massachusetts-based company that develops innovative optical technology to improve eye care accessibility. It manufactures a handheld device called QuickSee, which provides accurate refractive measurements for eyeglass prescriptions at the push of a button. This device is especially beneficial in rural and low-resource settings, addressing the vision needs of over one billion people globally. PlenOptika originated from research initiatives at the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium, where its founders aimed to tackle low vision issues through biomedical innovation. The company has received recognition from social innovation foundations and has collaborated with research centers in the United States, Spain, and India to refine its technology. By reducing the cost and space requirements of traditional autorefractors, PlenOptika enables more efficient and accessible eye care solutions for underserved communities.
Subtle Medical, Inc., a healthcare technology company, develops medical imaging software for clinical imaging centers and hospitals. Its product includes SubtleMR, an artificial intelligence-based image processing software that reduces image noise and increases image sharpness for non-contrast enhanced magnetic resonance imaging (MRI). It enables to reduce cost, imaging time, and radiation/contrast dose. The company was founded in 2017 and is based in Menlo Park, California.
Sarcura GmbH, founded in 2019 and located in Hinterstoder, Austria, specializes in developing a machine platform for the large-scale industrial manufacturing of personalized cell therapies aimed at treating cancer. The company utilizes semiconductor technology combined with microfluidic processing to achieve real-time control and manipulation at the cellular level. This innovative approach transforms traditional manufacturing paradigms, allowing for the production of cost-effective and safe cell therapies tailored to individual patient needs. Through its technology, Sarcura aims to enhance the accessibility and efficacy of patient-specific cancer treatments.
EarlySight SA is a Swiss company, established in 2016 and based in Lausanne, that focuses on developing innovative medical devices for the early detection and treatment of eye diseases. The company has created an advanced eye fundus camera that enhances retinal imaging through precise illumination and real-time correction of ocular aberrations. This device utilizes cellular-level imaging technology to identify subtle structural changes in the retina, allowing for effective monitoring of treatment outcomes in a quick and non-invasive manner. By facilitating the visualization of cell morphology within the retina, EarlySight aims to improve the capabilities of eye specialists in diagnosing and managing ocular conditions.
Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.
Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.
contextflow GmbH develops and provides machine learning and artificial intelligence (AI) based solutions for radiology image search and analysis. It offers 3D image-based information search solution, which delivers summary of clinical findings, similar reference cases, and associated differential diagnosis for supporting decisions. The company has strategic partnerships with Radiology Center, Boehringer Ingelheim, and Austrian Lung Fibrosis Association. contextflow GmbH was founded in 2016 and is headquartered in Vienna, Austria.
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.
Segmed, Inc. is a cloud-based platform that specializes in providing curated and anonymized radiology data for medical companies, primarily focused on supporting the development of artificial intelligence in healthcare. Founded in 2019 and headquartered in Menlo Park, California, Segmed's platform offers customized datasets tailored to the specific needs of its clients. The company aims to ensure that the data utilized for developing medical AI is diverse and representative, thereby reducing biases in healthcare applications. By building a robust infrastructure for accessing de-identified, structured medical imaging data, Segmed facilitates the creation of early disease detection and prediction models, ultimately contributing to the improvement of global healthcare outcomes.
Neurescue ApS, based in Copenhagen, Denmark, specializes in the development of medical devices aimed at treating cardiac arrest and hemorrhage. Founded in 2014, the company focuses on creating innovative cardiovascular solutions for emergency patients. Its flagship product, the safeREBOA device, is notable for being the first computer-aided aortic occlusion catheter, designed to enhance resuscitation rates and extend treatment time for critical patients. Neurescue is committed to advancing clinical practices through intelligent medical devices that aim to improve patient outcomes in emergency situations.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, focused on developing a metabolism-based liquid biopsy platform for the early detection and monitoring of cancer. Founded in 2017, Elypta's platform utilizes a new in vitro diagnostic laboratory assay kit to measure biomarkers in blood and urine, employing artificial intelligence algorithms to analyze data for cancer signatures. The company is actively involved in the clinical trial series AURORAX, which investigates the application of its technology in renal cell carcinoma, addressing aspects such as recurrence surveillance and treatment response monitoring. Elypta is exploring its platform's potential across various cancer indications, aiming to enhance early-stage cancer detection and improve patient outcomes.
PlenOptika, Inc. is a Massachusetts-based company that develops innovative optical technology to improve eye care accessibility. It manufactures a handheld device called QuickSee, which provides accurate refractive measurements for eyeglass prescriptions at the push of a button. This device is especially beneficial in rural and low-resource settings, addressing the vision needs of over one billion people globally. PlenOptika originated from research initiatives at the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium, where its founders aimed to tackle low vision issues through biomedical innovation. The company has received recognition from social innovation foundations and has collaborated with research centers in the United States, Spain, and India to refine its technology. By reducing the cost and space requirements of traditional autorefractors, PlenOptika enables more efficient and accessible eye care solutions for underserved communities.
TeiaCare is an Italian start-up founded in 2018, focused on enhancing technology and innovation in care homes. Based in Milan, the company operates in Italy and Spain and has a team of 15 employees supported by international investors. TeiaCare's primary product, Ancelia, is an AI-powered operating system that aims to improve transparency in care processes for residents and their families. This health technology solution includes a virtual assistant that generates smart alerts, reminders, and reports, addressing inefficiencies in monitoring post-acute hospital patients in nursing homes. Through its innovative approach, TeiaCare seeks to optimize resident assistance and streamline care home operations.
contextflow GmbH develops and provides machine learning and artificial intelligence (AI) based solutions for radiology image search and analysis. It offers 3D image-based information search solution, which delivers summary of clinical findings, similar reference cases, and associated differential diagnosis for supporting decisions. The company has strategic partnerships with Radiology Center, Boehringer Ingelheim, and Austrian Lung Fibrosis Association. contextflow GmbH was founded in 2016 and is headquartered in Vienna, Austria.
MindPeak GmbH is a Hamburg-based company founded in 2018 that specializes in developing software tools for visual diagnosis using artificial intelligence and deep learning. Its primary focus is on assisting pathologists in achieving reproducible cancer diagnostics. One of its key products, BreastAI, quantifies breast cancer immunohistochemistry (IHC) and can be integrated as a service within third-party software applications. MindPeak also optimizes workflows in pathological analysis, demonstrating its commitment to enhancing efficiency in the field. The company maintains a strategic partnership with Gestalt Diagnostics, further expanding its collaborative efforts in advancing diagnostic technologies.
Kheiron Medical Technologies Limited develops Mia, a mammography intelligent assessment tool that helps radiologists to detect breast cancer. Kheiron Medical Technologies Limited was formerly known as Maesterai Limited and changed its name to Kheiron Medical Technologies Limited in June 2016. The company was incorporated in 2016 and is based in London, United Kingdom with an additional location in San Francisco, California.
Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes.